Errol P Prens Selected Research

Hidradenitis Suppurativa

10/2022	IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.
1/2022	Registries, multicentre and genome-wide association studies in hidradenitis suppurativa.
12/2021	No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa.
11/2021	Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
7/2021	Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders.
1/2021	Target molecules for future hidradenitis suppurativa treatment.
1/2021	Anti-COVID-19 measurements for hidradenitis suppurativa patients.
12/2020	What causes hidradenitis suppurativa ?-15 years after.
1/2020	Lesional Inflammatory Profile in Hidradenitis Suppurativa Is Not Solely Driven by IL-1.
1/2019	Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Errol P Prens Research Topics

Disease

26	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 01/2003
20	Hidradenitis Suppurativa 10/2022 - 01/2009
10	Inflammation (Inflammations) 01/2020 - 01/2004
7	Skin Diseases (Skin Disease) 01/2021 - 10/2007
4	Atopic Dermatitis (Atopic Eczema) 01/2022 - 05/2008
4	Dermatitis 01/2020 - 05/2009
2	Dysbiosis 01/2022 - 01/2020
2	Abscess 08/2021 - 01/2019
2	Necrosis 01/2021 - 12/2009
2	COVID-19 01/2021 - 01/2021
2	Pain (Aches) 01/2019 - 12/2016
2	Port-Wine Stain (Nevus Flammeus) 01/2017 - 09/2016
2	Allergic Contact Dermatitis 01/2017 - 09/2016
2	Infections 01/2016 - 12/2012
2	Actinic Keratosis 01/2015 - 06/2013
1	Rupture 01/2022
1	Cysts 01/2022
1	Surgical Wound Infection 11/2021
1	Hemorrhage 11/2021
1	Psoriatic Arthritis 01/2020
1	Synovitis 01/2020
1	Headache (Headaches) 01/2019
1	Erythema 11/2018
1	Hereditary Complement Deficiency Diseases 01/2018
1	Cutaneous Lupus Erythematosus 01/2018
1	Vesiculobullous Skin Diseases (Subcorneal Pustular Dermatosis) 01/2018
1	Urticaria (Hives) 01/2018
1	Vasculitis (Vasculitides) 01/2018
1	Weight Loss (Weight Reduction) 01/2018
1	Pruritus (Itching) 10/2017
1	Injection Site Reaction 01/2016
1	Neoplasms (Cancer) 01/2015
1	Sepsis (Septicemia) 09/2013
1	Behcet Syndrome (Behcet's Syndrome) 04/2013
1	Parakeratosis 03/2013
1	Angiofibroma 01/2013
1	Neurofibroma 01/2013
1	Granuloma 01/2013

Drug/Important Bio-Agent (IBA)

9	CytokinesIBA 08/2021 - 01/2003
9	Imiquimod (Aldara)FDA LinkGeneric 01/2020 - 05/2009
5	Adalimumab (Humira)FDA Link 11/2021 - 12/2012
4	Interleukin-17 (Interleukin 17)IBA 10/2022 - 01/2020
4	Etanercept (Enbrel)FDA Link 01/2017 - 02/2011
4	Interleukin-23 (Interleukin 23)IBA 08/2015 - 05/2009
3	Complement System Proteins (Complement)IBA 01/2022 - 01/2018
3	Interleukin-1 (Interleukin 1)IBA 08/2021 - 02/2011
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 12/2009
3	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2017 - 04/2008
3	Interleukin-4 (Interleukin 4)IBA 08/2015 - 01/2011
2	Antimicrobial PeptidesIBA 01/2022 - 02/2011
2	OmigananIBA 01/2022 - 01/2020
2	apremilastIBA 07/2021 - 01/2019
2	Biological ProductsIBA 01/2021 - 01/2017
2	Pharmaceutical PreparationsIBA 01/2021 - 11/2018
2	Messenger RNA (mRNA)IBA 11/2018 - 01/2003
2	Ustekinumab (CNTO 1275)FDA Link 01/2017 - 04/2013
2	Sirolimus (Rapamycin)FDA Link 01/2017 - 09/2016
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2016 - 05/2008
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 06/2013 - 04/2008
2	RNA (Ribonucleic Acid)IBA 07/2011 - 04/2008
1	Interleukin-12 (IL 12)IBA 08/2021
1	S100A12 ProteinIBA 01/2021
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	indolicidinIBA 01/2020
1	ChemokinesIBA 01/2019
1	AntibodiesIBA 01/2018
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2018
1	Nucleic AcidsIBA 01/2017
1	NeuropeptidesIBA 01/2017
1	Toll-Like Receptor 7IBA 01/2017
1	Immunomodulating AgentsIBA 01/2017
1	bazlitoranIBA 01/2017
1	Triamcinolone (Aristocort)FDA Link 12/2016
1	C-Reactive ProteinIBA 01/2016
1	OligonucleotidesIBA 01/2016
1	FumaratesIBA 01/2016
1	Ficusin (Psoralen)IBA 01/2015
1	ORALIT (ORS)IBA 09/2014
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2013
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 09/2013
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 09/2013
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 06/2013
1	Caspase 14IBA 03/2013

Therapy/Procedure

11	Therapeutics 12/2020 - 05/2009
5	Lasers (Laser) 01/2020 - 01/2015
3	Phototherapy (Light Therapy) 01/2017 - 07/2011
2	Dye Lasers 01/2017 - 03/2010
1	Topical Administration 01/2022
1	Artificial Respiration (Mechanical Ventilation) 01/2021
1	Hair Removal (Depilation) 07/2018
1	Activities of Daily Living (ADL) 10/2017
1	Skin Transplantation (Skin Grafting) 06/2017
1	Drug Tapering 01/2017
1	Solid-State Lasers 01/2017
1	Denervation 01/2017
1	Intralesional Injections 12/2016
1	Photochemotherapy (Photodynamic Therapy) 01/2015
1	Laser Therapy (Surgery, Laser) 01/2013